On October 10, 2023 Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immune-oncology antibody-drug-conjugate company developing an innovative drug platform for the treatment of cancer, reported that the Company will present new preclinical data on L-DOS47 in combination with PD1 checkpoint inhibition at the 2023 AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) in the Hynes Convention Center, Boston, via in person attendance, October 11-15, 2023 (Press release, Helix BioPharma, OCT 10, 2023, View Source [SID1234635947]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Presentation Details:
Title: Neutralizing Acidosis with ADC L-DOS47 Urease Immunoconjugate Enhances Response to Anti-PD1 Checkpoint Blockade in A Preclinical Orthotopic Model of Pancreatic Adenocarcinoma
Abstract Number: 35494
Poster Presentation Date and Time: Friday, October 13, 12:30 pm – 4:00 pm
Location: Level 2, Exhibit Hall D Poster Session B,
Poster Number: B125
During the conference, Helix will highlight the enhanced effects of anti-PD1 immunotherapy when combined with L-DOS47 in an orthotopic Pancreatic tumor model in mice. The drug has already been administered to over 120 patients in the clinic across 4 Toronto, Ontario | October 10, 2023 07:01 AM Eastern Daylight Time clinical trials and has been shown to be safe and well tolerated. Additionally, L-DOS47 has also demonstrated promising anti-tumor activity across a range of doses, both as monotherapy and in combination with chemotherapy agents. The Company is open to collaborating with the right partner(s) to explore potential synergies with anti-PD1 and other treatment regimens.
"We are enthusiastic about the results of these studies, which showcase a distinctive ADC platform. This platform has the capability to synergize effectively with a wide range of approaches, such as chemotherapy, radiation therapy, immunotherapy, and emerging cell therapies. This synergy aims to boost effectiveness while minimizing safety issues." said Jacek Antas, Helix’s Chief Executive Officer. More details about the AACR (Free AACR Whitepaper)-NCI-EORTC Conference are available on the official website.